Roche’s Vabysmo to offer ‘fierce competition’ to Regeneron’s Eylea
Summary : Roche’s Vabysmo is having a strong start with doctors, but it has a long way to go if it wants…
Summary : Roche’s Vabysmo is having a strong start with doctors, but it has a long way to go if it wants…
Synopsis: The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or…
Novartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T cell therapy Kymriah (Tisagenlecleucel) as third-line therapy…
Keypoints USFDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early NSCLC Tecentriq treatment reduced the risk of disease recurrence…